Prostate biopsy is a procedure in which small hollow needle-core samples are removed from a man's prostate gland to be examined for the presence of prostate cancer. It is typically performed when the result from a PSA blood test is high. It may also be considered advisable after a digital rectal exam (DRE) finds possible abnormality. PSA screening is controversial as PSA may become elevated due to non-cancerous conditions such as benign prostatic hyperplasia (BPH), by infection, or by manipulation of the prostate during surgery or catheterization. Additionally many prostate cancers detected by screening develop so slowly that they would not cause problems during a man's lifetime, making the complications due to treatment unnecessary.
The most frequent side effect of the procedure is blood in the urine (31%). Other side effects may include infection (0.9%) and death (0.2%).
The procedure may be performed transrectally, through the urethra or through the perineum. The most common approach is transrectally, and historically this was done with tactile finger guidance. The most common method of prostate biopsy was transrectal ultrasound-guided prostate (TRUS) biopsy.
Extended biopsy schemes take 12 to 14 cores from the prostate gland through a thin needle in a systematic fashion from different regions of the prostate.
A biopsy procedure with a higher rate of cancer detection is template prostate mapping (TPM) or transperineal template-guided mapping biopsy (TTMB), whereby typically 50 to 60 samples are taken of the prostate through the outer skin between the rectum and scrotum, to thoroughly sample and map the entire prostate, through a template with holes every 5mm, usually under a general or spinal anaesthetic.
Antibiotics are usually prescribed to minimize the risk of infection. A healthcare provider may also prescribe an enema to be taken in the morning of the procedure. During the transrectal procedure, an ultrasound probe is inserted into the rectum to assist in guiding the biopsy needles.
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
L'antigène prostatique spécifique (PSA, pour prostate-specific antigen) est une protéine fabriquée exclusivement par la prostate ; il sert à liquéfier le sperme afin de faciliter le déplacement des spermatozoïdes. . vignette|Risque de cancer de la prostate pour deux groupes d'âge, basé sur la fraction de PSA libre exprimée en % du PSA total. Le PSA est normalement présent dans le sang de tous les hommes à un taux infime. Le dosage de son taux sanguin est utilisé pour le diagnostic et le suivi du cancer de la prostate.
L'hypertrophie bénigne de la prostate aussi appelée hyperplasie bénigne de la prostate (HBP) ou hyperplasie adénomyomateuse de la prostate ou plus communément adénome prostatique est une tumeur bénigne qui se développe aux dépens de la partie crâniale de la prostate. Elle touche les sujets âgés de plus de 50 ans. En cas d'hypertrophie bénigne de la prostate, la prostate devient plus grande et exerce plus de pression sur l'urètre et la vessie, interférant ainsi avec l'écoulement normal de l'urine.
Explore l'interprétation des réponses binaires, les fonctions de liaison, la régression logistique et la sélection des modèles à l'aide de déviances et de critères d'information.
Background Currently, multi-parametric prostate MRI (mpMRI) consists of a qualitative T-2, diffusion weighted, and dynamic contrast enhanced imaging. Quantification of T-2 imaging might further standardize PCa detection and support artificial intelligence ...
Purpose Purpose of this study is to evaluate the diagnostic accuracy of quantitative T2/ADC values in differentiating between PCa and lesions showing non-specific inflammatory infiltrates and atrophy, features of chronic prostatitis, as the most common his ...
In failure-time settings, a competing event is any event that makes it impossible for the event of interest to occur. For example, cardiovascular disease death is a competing event for prostate cancer death because an individual cannot die of prostate canc ...